Bristol Myers Squibb, Eli Lilly and Novo are among the limited partners in the pharmaceutical-focused venture firm's BGV IV fund, which has reached its final close.

Netherlands-based, healthcare-focused venture capital firm BioGeneration Ventures has closed its fourth fund at €140m (roughly $170m) having picking up commitments from pharmaceutical companies Eli Lilly, Bristol Myers Squibb (BMS) and Novo. Novo backed the fund through corporate VC vehicle Novo Ventures, and Schroder Adveq, Industriens Pension, KfW Capital and European Investment Fund (EIF) are also…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.